Microbicide Vaginal Rings: Technological Challenges and Clinical Development

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)
1167 Downloads (Pure)

Abstract

Vaginal rings (VRs) are flexible, torus-shaped, polymeric devices designed to sustain delivery of pharmaceutical drugs to the vagina for clinical benefit. Following first report in a 1970 patent application, several steroid-releasing VR products have since been marketed for use in hormone replacement therapy and contraception. Since 2002, there has been growing interest in the use of VR technology for delivery of drugs that can reduce the risk of sexual acquisition of human immunodeficiency virus type 1 (HIV-1), the causative agent of acquired immunodeficiency syndrome (AIDS). Although no vaginally-administered product has yet been approved for HIV reduction/prevention, extensive research efforts are continuing and a number of VR devices offering sustained release of so-called ‘HIV microbicide’ compounds are currently being evaluated in late-stage clinical studies. This review article provides an overview of the published scientific literature within this important field of research, focusing primarily on articles published within peer-reviewed journal publications. Many important aspects of microbicide-releasing VR technology are discussed, with a particular emphasis on the technological, manufacturing and clinical challenges that have emerged in recent years.
Original languageEnglish
Pages (from-to)33-56
Number of pages24
JournalAdvanced Drug Delivery Reviews
Volume103
Early online date30 Jan 2016
DOIs
Publication statusPublished - 01 Aug 2016

Keywords

  • vaginal rings
  • vaginal drug delivery
  • adherence
  • controlled release
  • HIV microbicides
  • antiretrovirals
  • HIV prevention

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Microbicide Vaginal Rings: Technological Challenges and Clinical Development'. Together they form a unique fingerprint.

Cite this